Apyx Medical (NASDAQ:APYX) Issues Quarterly Earnings Results

Apyx Medical (NASDAQ:APYX) released its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05, FiscalAI reports. The firm had revenue of $14.03 million for the quarter, compared to analyst estimates of $13.29 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported third-quarter revenue of $14 million, up 9% year over year, led by 17% growth in Surgical Aesthetics. OEM revenue fell 41.5%, partially offsetting that growth.
• The company said AYON’s power-liposuction rollout is underway and surgeon feedback has been positive; management sees additional growth potential as it pursues regulatory approvals in international markets, though it gave no approval timelines.
• Apyx reported positive EBITDA on a trailing 12-month basis and $0.4 million in adjusted EBITDA for the quarter, versus a loss a year earlier. Operating cash use also declined year over year, and cash stood at $25.8 million at quarter-end.
• Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target to $41 million–$42.5 million from less than $45 million. It now expects full-year gross margins of 63%–64%.

Apyx Medical Price Performance

Shares of APYX stock traded up $0.46 on Thursday, hitting $3.04. The company’s stock had a trading volume of 994,957 shares, compared to its average volume of 122,382. Apyx Medical has a fifty-two week low of $2.25 and a fifty-two week high of $5.08. The firm’s fifty day moving average price is $2.74 and its 200-day moving average price is $3.59. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Wall Street Analysts Forecast Growth

APYX has been the topic of several research analyst reports. Maxim Group started coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They set a “buy” rating and a $6.00 price target on the stock. HC Wainwright assumed coverage on Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. Finally, Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.